Drug Price Watchdog Making Unfair Decisions, Indian Industry Lobby Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Lack of transparency in price setting, misapplication of the Spurious Drugs law and a new requirement that already-approved fixed-dose combinations be treated as new drugs are high on the grievance list.
You may also be interested in...
Spurious Drugs Issue: Indian Government Proposes Cash Rewards For Informers; Industry Supportive
NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.